Cell News and Research

RSS

Lab on a Chip for research on oxygen impact on brain cells

A mini-laboratory that makes it possible, among other things, to study how brain cells in stroke patients are affected by lack of oxygen is being developed by a research team at Luleå University of Technology in Sweden. Lab on a Chip is what the scientists are calling their mini-lab, which is expected to facilitate studies of all sorts of biological cells and how they are affected by different medicines, chemical substances, etc.

22 Mar 2010

Cancer radiotherapy can increase risk of cardiovascular disease later in life

For an as yet unknown reason, cancer radiotherapy can increase the risk of cardiovascular disease later in life, a problem that is growing as more and more people survive their cancer diagnosis. New research from Karolinska Institutet now suggests that sustained inflammation induced by post-radiotherapy changes in the gene expression in the arteries could be the cause.

22 Mar 2010

ILSI Biomed Israel 2010 international conference to be held in Tel Aviv

Set against the backdrop of the global market recovery and the recent proliferation of the life sciences field, this June’s ILSI Biomed Israel 2010 international conference will be attended by the most prominent figures in the biotechnology, pharma and medical device sectors.

22 Mar 2010

AARDA launches campaign on family AQ

In honor of the designation of March as National Autoimmune Disease Awareness Month by the U.S. Senate on March 4, 2010, the American Autoimmune Related Diseases Association (AARDA) wants to help you learn your family's AQ. AQ is a play on IQ that stands for Autoimmune Quotient. It's about knowing how likely you or a loved one is to develop an autoimmune disease, based on the prevalence of these diseases and your family history. The campaign features AARDA National Spokesperson and Actress Kellie Martin, best known for her memorable roles on "E.R." and "Life Goes On."

22 Mar 2010

Nanobotmodels animates future DNA repairing process

Nanobotmodels Company made detail animation of DNA-repair process using nanomechanical robot. You can see all stages of repair in this animation, based on DNA-nanorobot model.

22 Mar 2010

Asuragen appoints BMD as exclusive distributor of Signature Oncology Products in France

Asuragen, Inc., a leader in the development of molecular diagnostics, announced today the appointment of Biomedical Diagnostics SA, a leading medical diagnostic company in Europe, as its exclusive distributor of Signature® Oncology Products in France. Asuragen’s Signature Oncology Portfolio comprises multiplex assays for the detection of mutations in solid and hematologic malignancies.

22 Mar 2010

Nanotechnology weapons for cancer

US Researchers have come up with new nanoparticle robots that are essentially a tiny army that can travel in the blood till they reach the cancers and then tweak some important cancer causing genes that can cure the cancer.

22 Mar 2010

Mayo Clinic co-led research finds first gene linked to lung cancer in "never smokers"

A five-center collaborative study that scanned the genomes of thousands of "never smokers" diagnosed with lung cancer as well as healthy never smokers has found a gene they say could be responsible for a significant number of those cancers.

22 Mar 2010

JDRF to begin diabetes research collaboration on drugs for replicating insulin-producing cells

The Juvenile Diabetes Research Foundation, a leader in setting the agenda for diabetes research worldwide, said today that it will begin a diabetes research collaboration with Pfizer, Hadassah Medical Organization, and The Hebrew University of Jerusalem on drugs to replicate and regenerate insulin-producing cells in people with type 1 diabetes.

22 Mar 2010

Caltech-led trial demonstrates feasibility of nanoparticles and RNAi-based therapeutics for treating cancer

A California Institute of Technology -led team of researchers and clinicians has published the first proof that a targeted nanoparticle-used as an experimental therapeutic and injected directly into a patient's bloodstream-can traffic into tumors, deliver double-stranded small interfering RNAs (siRNAs), and turn off an important cancer gene using a mechanism known as RNA interference (RNAi).

22 Mar 2010

Scientists identify new growth factor that stimulates expansion of hematopoietic stem cells

Scientists at Duke University Medical Center have identified a new growth factor that stimulates the expansion and regeneration of hematopoietic (blood-forming) stem cells in culture and in laboratory animals. The discovery, appearing in the journal Nature Medicine, may help researchers overcome one of the most frustrating barriers to cellular therapy: the fact that stem cells are so few in number and so stubbornly resistant to expansion.

22 Mar 2010

Novel ways of killing TB causing bacteria discovered

Researchers at Albert Einstein College of Medicine of Yeshiva University have found two novel ways of killing the bacteria that cause tuberculosis (TB), a disease responsible for an estimated two million deaths each year. The findings, published in the March 21 online issue of Nature Chemical Biology, could lead to a potent TB therapy that would also prevent resistant TB strains from developing.

22 Mar 2010

Genetic study may help develop potential treatment strategies for stiff skin syndrome

By studying the genetics of a rare inherited disorder called stiff skin syndrome, researchers at the Johns Hopkins University School of Medicine have learned more about scleroderma, a condition affecting about one in 5,000 people that leads to hardening of the skin as well as other debilitating and often life-threatening problems.

20 Mar 2010

EUREKA project develops unique range of antibodies

EUREKA project E! 3424 RECAN has developed a range of unique and highly specific monoclonal and polyclonal antibodies - the proteins produced in the blood which counteract bacteria, viruses or cancerous cells.

20 Mar 2010

Effective defense against HIV: Acne drug minocycline

Johns Hopkins scientists have found that a safe and inexpensive antibiotic in use since the 1970s for treating acne effectively targets infected immune cells in which HIV, the virus that causes AIDS, lies dormant and prevents them from reactivating and replicating.

20 Mar 2010

Turning microRNAs into novel drugs

Researchers around the globe are working on turning microRNAs, over 5,000 of which already have been identified, into novel drugs for a wide range of applications, reports Genetic Engineering & Biotechnology News (GEN). These noncoding single-stranded RNAs act through binding to complementary mRNA sequences, thus preventing their translation into protein or accelerating mRNA breakdown, according to the March 15 issue of GEN.

20 Mar 2010

Pressure BioSciences announces presentations on advantages of PCT

Pressure BioSciences, Inc. today announced that five presentations on the advantages of pressure cycling technology (PCT) in the preparation, processing, identification, and quantification of proteins were made at last week's annual meeting of US HUPO (Human Proteomics Organization) in Denver, Colorado.

From Thermo Fisher Scientific Inc. 19 Mar 2010

White paper describes health and economic burden of diabetes on Americans

PositiveID Corporation announced today that it has published a white paper entitled “Fixing the Black Hole in Diabetes Management,” which describes the health and economic burden of diabetes on Americans and our economy.

19 Mar 2010

European CHMP issues positive opinion for Roche's Tarceva as maintenance therapy for NSCLC

Roche today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of Tarceva(R) (erlotinib) as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely unchanged) after initial chemotherapy. The CHMP positive opinion clears the way for European Union approval and means that this group of patients may soon be able to benefit from earlier treatment with Tarceva.

19 Mar 2010

CHMP issues positive opinion recommending approval of Tarceva as monotherapy for NSCLC

OSI Pharmaceuticals, Inc. announced today that its international partner for Tarceva® (erlotinib), Roche, informed OSI that the European Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of Tarceva as monotherapy for maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with stable disease following four cycles of standard platinum-based first-line chemotherapy.

19 Mar 2010

Cell News and Research

Lab on a Chip for research on oxygen impact on brain cells

Cancer radiotherapy can increase risk of cardiovascular disease later in life

ILSI Biomed Israel 2010 international conference to be held in Tel Aviv

AARDA launches campaign on family AQ

Nanobotmodels animates future DNA repairing process

Asuragen appoints BMD as exclusive distributor of Signature Oncology Products in France

Nanotechnology weapons for cancer

Mayo Clinic co-led research finds first gene linked to lung cancer in "never smokers"

JDRF to begin diabetes research collaboration on drugs for replicating insulin-producing cells

Caltech-led trial demonstrates feasibility of nanoparticles and RNAi-based therapeutics for treating cancer

Scientists identify new growth factor that stimulates expansion of hematopoietic stem cells

Novel ways of killing TB causing bacteria discovered

Genetic study may help develop potential treatment strategies for stiff skin syndrome

EUREKA project develops unique range of antibodies

Effective defense against HIV: Acne drug minocycline

Turning microRNAs into novel drugs

Pressure BioSciences announces presentations on advantages of PCT

White paper describes health and economic burden of diabetes on Americans

European CHMP issues positive opinion for Roche's Tarceva as maintenance therapy for NSCLC

CHMP issues positive opinion recommending approval of Tarceva as monotherapy for NSCLC

What are the challenges of cell line development? eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo